Published in J Natl Cancer Inst on January 15, 2003
Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res (2012) 1.85
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol (2011) 1.57
Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. Gynecol Oncol (2015) 1.43
Adjuvant chemotherapy after complete resection of non-small cell lung cancer. Dtsch Arztebl Int (2008) 1.39
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol (2008) 1.22
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev (2012) 1.11
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev (2012) 0.98
Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One (2009) 0.96
Epithelial ovarian cancer: An overview. World J Transl Med (2014) 0.91
Adnexal masses suspected to be benign treated with laparoscopy. JSLS (2012) 0.87
Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. Semin Oncol (2008) 0.85
Surgical outcomes in women with ovarian cancer. Can J Surg (2008) 0.84
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int (2013) 0.84
SEOM guideline in ovarian cancer 2014. Clin Transl Oncol (2014) 0.84
Optimal treatment of early-stage ovarian cancer. Ann Oncol (2014) 0.83
Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res (2016) 0.82
The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res (2012) 0.81
Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients. PLoS One (2015) 0.81
Early-stage ovarian cancer: to treat or not to treat. J Natl Cancer Inst (2003) 0.79
Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. Int J Clin Oncol (2012) 0.78
Clinical utility of image-guided peritoneal and omental biopsy. Nat Rev Clin Oncol (2010) 0.78
Doublet chemotherapy in the elderly patient with ovarian cancer. Oncologist (2012) 0.78
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer (2016) 0.77
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol (2011) 0.77
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer (2006) 0.77
Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma. Int Sch Res Notices (2014) 0.77
Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer. Oncol Lett (2016) 0.76
Antiangiogenic therapies in ovarian cancer. Memo (2016) 0.76
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol (2013) 0.76
Recent advances in systemic treatments for ovarian cancer. Cancer Imaging (2012) 0.76
Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry. Curr Oncol (2016) 0.75
Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer. Obstet Gynecol (2016) 0.75
If the Mountain Does Not Come to Mohammad: The Significance of Guest Operations for Early Stage Ovarian Cancer. J Gynecol Surg (2014) 0.75
Comparison of Laparoscopy and Laparotomy in Surgical Staging of Apparent Early Ovarian Cancer: 13-year Experience. Medicine (Baltimore) (2016) 0.75
Re: Adjuvant chemotherapy in patients with early-stage ovarian cancer. J Natl Cancer Inst (2003) 0.75
Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. Ecancermedicalscience (2015) 0.75
SEOM Clinical Guideline in ovarian cancer (2016). Clin Transl Oncol (2016) 0.75
Changing Practice of Gynecologic Oncology based on Current Evidence. Med J Armed Forces India (2011) 0.75
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer (2016) 0.75
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer. J Clin Oncol (2016) 0.75
Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer. Obstet Gynecol (2017) 0.75
Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression. Oncol Lett (2017) 0.75
Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens. J Gynecol Oncol (2018) 0.75
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol (2014) 6.28
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Endometrial cancer. Lancet (2005) 5.50
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet (2009) 4.58
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet (2011) 4.36
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (2010) 3.78
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol (2008) 3.75
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol (2013) 3.36
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol (2009) 3.19
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg (2006) 2.97
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Results of the European Glaucoma Prevention Study. Ophthalmology (2005) 2.91
CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax (2011) 2.88
Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol (2014) 2.81
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol (2007) 2.73
Clinical outcome after radical excision of moderate-severe endometriosis with or without bowel resection and reanastomosis: a prospective cohort study. Ann Surg (2014) 2.71
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol (2013) 2.69
Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res (2007) 2.54
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 2.50
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003) 2.44
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst (2007) 2.42
Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol (2007) 2.31
Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology (2006) 2.28
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol (2011) 2.27
Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer (2004) 2.26
Clinical management of uterine sarcomas. Lancet Oncol (2009) 2.18
Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol (2009) 2.14
Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol (2011) 2.10
Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. BMJ (2008) 2.10
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer (2011) 2.09
Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw. Clin Nucl Med (2011) 2.04
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology (2006) 2.01
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst (2007) 2.01
Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol (2008) 2.01
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet (2011) 1.84
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84
History of the FIGO cancer staging system. Int J Gynaecol Obstet (2008) 1.81
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol (2007) 1.80
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. Am J Obstet Gynecol (2007) 1.80
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst (2003) 1.75
Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol (2006) 1.73
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol (2010) 1.73
Robotic approach for cervical cancer: comparison with laparotomy: a case control study. Gynecol Oncol (2009) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer (2003) 1.72
Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol (2005) 1.67
Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol (2004) 1.66
Ovarian cancer. Crit Rev Oncol Hematol (2006) 1.64
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev (2009) 1.63
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer (2005) 1.60
Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol (2010) 1.60
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer (2010) 1.57
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation (2002) 1.57
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol (2003) 1.57
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ (2010) 1.55
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55